Buprenorphine and Imatinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Imatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Imatinib (Gleevec) slows down a liver enzyme called CYP3A4, which is one of the main ways your body breaks down buprenorphine. When that enzyme is blocked, buprenorphine can build up in your blood and its effects can last longer and feel stronger.
The main thing to watch for is too much sedation or slowed, shallow breathing. This is worth taking seriously, but the good news is your care team can manage it easily by adjusting your buprenorphine dose and watching you a little more closely. Please don't stop either medicine on your own. Just check in with your pharmacist or doctor so they can keep you safe.
Mechanism: Imatinib inhibits CYP3A4, reducing buprenorphine metabolism and increasing buprenorphine plasma concentrations (increased AUC/Cmax). Buprenorphine is the active drug here, not a prodrug, so inhibition increases opioid effect.
Effect: Prolonged opioid effects including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
Management:
- If starting imatinib, consider reducing the buprenorphine dose until stable effects are achieved; monitor frequently for sedation and respiratory depression.
- On imatinib discontinuation, anticipate reduced buprenorphine levels and monitor for withdrawal; a dose increase may be needed.
- For depot/subQ buprenorphine (Sublocade, Brixadi), fine titration is limited, so monitor closely for over-medication; consider a formulation allowing precise dose adjustment if needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inhibitor can raise buprenorphine plasma levels, which may extend opioid effects such as respiratory depression. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, it may be appropriate to lower the buprenorphine dose until drug effects stabilize, with frequent monitoring for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in someone being treated with buprenorphine, an increase in the buprenorphine dose may be warranted until stable drug effects are reached, along with monitoring for indications of opioid withdrawal2. Should dose adjustment not be feasible once the CYP3A4 inhibitor is no longer present, the patient should be switched back to a buprenorphine formulation that allows finer dose titration. For patients moved from transmucosal buprenorphine given alongside CYP3A4 inhibitors, confirm through monitoring that the buprenorphine plasma concentration delivered by subQ buprenorphine is sufficient. Patients already receiving subQ buprenorphine who then need a CYP3A4 inhibitor should be watched for evidence of over-medication. If signs and symptoms of buprenorphine toxicity or overdose develop but the concurrent medication cannot be lowered or stopped, reduce the buprenorphine dose. When the available doses do not allow the target dose to be reached, discontinue therapy and manage the patient with a buprenorphine formulation that permits more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medications as prescribed unless your care team tells you otherwise. This interaction is manageable with the right adjustments and monitoring.
- Your team may lower your buprenorphine dose while you are on imatinib and watch you more closely for excess drowsiness or slowed breathing.
- When imatinib is stopped, your buprenorphine dose may need to be raised again, and they will watch for withdrawal symptoms.
- If you use a long-acting injectable form (like Sublocade or Brixadi), tell your team, since the dose can be harder to fine-tune and may need closer monitoring.
Call your prescriber or pharmacist if you feel unusually sleepy, confused, or notice slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concomitantly administered CYP3A4 inhibitors on buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Imatinib together?
Imatinib can raise buprenorphine levels and increase the risk of excess sedation and slowed breathing. Don't change anything on your own; your care team can safely manage this by adjusting your buprenorphine dose and monitoring you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Imatinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Imatinib interaction managed?
Keep taking both medications as prescribed unless your care team tells you otherwise. This interaction is manageable with the right adjustments and monitoring. Your team may lower your buprenorphine dose while you are on imatinib and watch you more closely for excess drowsiness or slowed breathing. When imatinib is stopped, your buprenorphine dose may need to be raised again, and they will watch f… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Imatinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Imatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist